Experimental cancer drug LB101 trial halted early
NCT ID NCT05821777
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 22 times
Summary
This early-stage study tested a new drug called LB101 in 25 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The trial was terminated early, so results are limited and no clear benefit was established.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
NEXT Oncology - Dallas
Irving, Texas, 75039, United States
-
Sarah Cannon Research Institute at Florida Cancer Specialists
Sarasota, Florida, 34232, United States
-
Sarah Cannon Research Institute at HealthONE.
Denver, Colorado, 80218, United States
-
Sarah Cannon Research Institute at Tennessee Oncology Nashville
Nashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.